Shots:
- China’s NMPA has accepted sNDA of toripalimab + disitamab vedotin for the treatment of HER2+ locally advanced or metastatic urothelial carcinoma (LA/M UC)
- sNDA was backed by P-III (RC48-C016) trial assessing toripalimab + disitamab vedotin vs gemcitabine + cisplatin/carboplatin across 74 centres in systemic-treatment-naïve Chinese pts with HER2+ LA/M UC
- Toripalimab is an anti-PD-1 monoclonal antibody that blocks PD-1/PD-L1 pathway to reduce immune suppression & enhance anti-tumor immune responses, while disitamab vedotin is an ADC designed to target the HER2 receptor
Ref: Junshi Biosciences| Image: Junshi Biosciences| Press Release
Related News:- Arvinas Reports the US FDA’s NDA Acceptance of Vepdegestrant for ESR1-Mutated Breast Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
